NeoPhore Appoints Michael Shih as CEO to Propel Growth
Portfolio - People | Dec 31, 2024 | EIN
NeoPhore, a pioneering neoantigen immuno-oncology company, has named Michael Shih as its new CEO. Shih, with nearly 20 years of experience in business development, licensing, and M&A, comes from his role as VP of Corporate Development at Kite Pharma. His career also includes senior positions at Biogen, Sanofi, Epizyme, Forest Laboratories, and Eisai. The appointment comes after NeoPhore's successful Series B funding, led by Bristol Myers Squibb, which aims to enhance NeoPhore's trajectory towards becoming a clinical company. NeoPhore's focus is on developing unique small molecule drugs targeting the MMR pathway to revolutionize cancer treatment.
Sectors
- Pharmaceutical
- Biotechnology
Geography
- United States – Michael Shih's career and the headquarters of several companies he worked with, such as Kite Pharma, Biogen, and Sanofi, are based in the U.S.
Industry
- Pharmaceutical – NeoPhore operates within the pharmaceutical industry, focusing on developing cancer treatments through innovative drug therapies.
- Biotechnology – The company specializes in biotech solutions, advancing immuno-oncology therapies through the MMR pathway.
Financials
- Series B Financing – NeoPhore recently closed a Series B financing round, which was oversubscribed and supported by Bristol Myers Squibb.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| NeoPhore | Target Company | Company | A small molecule neoantigen immuno-oncology company focusing on treatments targeting the MMR pathway to improve cancer therapies. |
| Michael Shih | CEO | Person | Recently appointed CEO of NeoPhore, with extensive experience in corporate development and transactions in the pharmaceutical sector. |
| Bristol Myers Squibb | Financier | Company | Supported NeoPhore's Series B financing, aimed at bolstering the company's growth strategy. |
| Kite Pharma | Former Employer | Company | Michael Shih's previous employer where he served as VP of Corporate Development, leading business opportunities. |
| Biogen | Former Employer | Company | Shih's former employer, where he was Senior VP and Head of Business Development. |
| Sanofi | Former Employer | Company | A former employer of Shih, where he handled global transactions. |
| Epizyme | Former Employer | Company | A biotech company where Shih held senior business development roles. |
| Forest Laboratories | Former Employer | Company | One of Shih's previous roles in business development. |
| Eisai | Former Employer | Company | Worked as VP and in senior legal roles focusing on licensing and corporate transactions. |